Cephalon, Inc.

Julia Rozenfeld

Anthony Gerard Doyle

Adam Clarke

Matthew Pollard

Lynn Dorothy Poulton

Bridget Ann Cooksey

Mark Terence Liddament

Sachin Badrinath Surade

Marta Szabat

Anna Maria Matilda Quigley

Anna Mikaela Bracken

David S Wilson, Jr

Kim Tran Yap

Debasish Sen

David Laine

Danyal Butt

Hugh Macrae

Jenny Vo

Paul Ayton

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PAR-2 and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PAR-2 block the interaction between a PAR-2 activating ligand and an extracellular domain of PAR-2, and/or blocks PAR-2 activation by a PAR-2 activating ligand, In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with increased expression of PAR-2 and/or diseases or conditions that can be alleviated by antagonizing activation of PAR-2 by a PAR-2 activating ligand (e.g., airway diseases, skin diseases, cancer, orofacial granulomatosis, inflammatory conditions, and pain associated with various diseases or conditions).

Anti-PAR-2 antibodies and methods of use thereof

The present disclosure generally relates to anti-PACAP antibodies, pharmaceutical compositions comprising such antibodies, and methods of producing and using such antibodies.

Compositions and methods for anti-PACAP antibodies

Disclosed herein are modified human interleukin-2 (hIL-2) proteins, human antibody molecules, or antigen-binding fragments thereof, that immunospecifically bind to human programmed cell death protein-1 (hPD-1), and immunoconjugates comprising the same.

Anti-pd-1 antibody-attenuated IL-2 immunoconjugates and uses thereof

Growing community of inventors

Gordon, Australia

Julia Rozenfeld